Sponsor content
216 result(s) found, displaying 1 to 10
-
Australian public assessment report (AusPar)Qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. The use of this vaccine should be in accordance with official recommendations.
-
Australian public assessment report (AusPar)Adzynma is a recombinant ADAMTS13 enzyme replacement therapy that has been approved for the treatment of ADAMTS13 deficiency in patients with congenital thrombotic thrombocytopenic purpura (cTTP).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for QDENGA dengue tetravalent vaccine (live, attenuated) dengue virus serotypes 1, 2, 3, and 4, powder (vial) & solvent (PFS) for injection.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for QDENGA dengue tetravalent vaccine (live, attenuated) dengue virus serotypes 1, 2, 3, and 4, powder (vial) & solvent (vial) for injection.
-
Prescription medicine decision summaryQdenga (live, attenuated - dengue virus serotypes 1, 2, 3, and 4) is a vaccine approved to provide protection against dengue disease for adults, adolescents, and children aged 4 years and over.
-
Designation or determinationOrphan drug
-
Designation or determinationPriority review
-
Prescription medicine registrationActive ingredients: dengue virus serotype 1, dengue virus serotype 2, dengue virus serotype 3, dengue virus serotype 4.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ADZYNMA apadamtase alfa/cinaxadamtase alfa 1500 IU powder and solvent for injection vials.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ADZYNMA apadamtase alfa/cinaxadamtase alfa 500 IU powder and solvent for injection vials.